Shattuck Labs (STTK) Cash from Financing Activities (2019 - 2026)
Shattuck Labs (STTK) reported Cash from Financing Activities of $25.8 million for Q1 2026, up 45368.42% year-over-year from N/an in Q1 2025, and up 19155.97% quarter-over-quarter from $134000.0 in Q4 2025.
Shattuck Labs (STTK) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has 8 years of Cash from Financing Activities data on file, last reported at $25.8 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $25.8 million, up 45368.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $70.4 million (up 7606.13% YoY), and the FY2025 annual result was $44.6 million, up 5563.79% from the prior year.
- Cash from Financing Activities advanced to $25.8 million in Q1 2026 per STTK's latest filing, from $134000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $48.6 million in Q4 2023 and troughed at -$184000.0 in Q1 2024.
- A 5-year average of $8.6 million and a median of $30000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 100.15% in 2024, then jumped 193365.22% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $27000.0 in 2022, then soared by 179759.26% to $48.6 million in 2023, then slumped by 100.15% to -$72000.0 in 2024, then jumped by 286.11% to $134000.0 in 2025, then jumped by 19155.97% to $25.8 million in 2026.
- Business Quant data shows STTK's Cash from Financing Activities at $25.8 million in Q1 2026, $134000.0 in Q4 2025, and $44.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Shattuck Labs | 190.32 Mn | 190.32 Mn | - | 25.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.80 Mn |
| Mar 31, 2026 | 25.80 Mn |
| Dec 31, 2025 | 134,000.00 |
| Dec 31, 2025 | 134,000.00 |
| Sep 30, 2025 | 44.50 Mn |
| Sep 30, 2025 | 44.50 Mn |
| Mar 31, 2025 | -57,000.00 |
| Mar 31, 2025 | -57,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | -184,000.00 |
| Mar 31, 2024 | -184,000.00 |
| Dec 31, 2023 | 48.56 Mn |
| Dec 31, 2023 | 48.56 Mn |
| Sep 30, 2023 | 21,000.00 |
| Sep 30, 2023 | 21,000.00 |